Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Bronze Orange	NCIT_C74553
Aminopterin Sodium	NCIT_C74554	[The sodium salt of a pterin derivative with antineoplastic and immunosuppressive properties. As a folate analogue, aminopterin competes for the folate binding site of the enzyme dihydrofolate reductase, thereby blocking tetrahydrofolate synthesis, and resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. (NCI04)]
Dihydrofolate Reductase Inhibitor	NCIT_C2153	[Any substance that inhibits dihydrofolate reductase, an enzyme that catalyzes the conversion of dihydrofolate to tetrahydrofolate, an essential reaction for de novo glycine and purine synthesis. Inhibition of dihydrofolate reductase interferes with DNA and protein synthesis.]
Folate Antagonist	NCIT_C511	[A compound with a chemical structure similar to folic acid. Folate antagonists inhibit one or more folate-dependent enzymes, resulting in decreased DNA, RNA and protein synthesis.]
CDISC SDTM Subject Characteristic Test Code Terminology	NCIT_C74559	[Terminology codelist used for Subject Characteristic Codes within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.]
Oily Skin	NCIT_C74591	[The pores of the skin are generally large and visible with a coarse or thick texture. The skin has a tendency to look dull and greasy and feels oily to the touch.]
Dry Skin	NCIT_C74592	[The pores are generally fine with a papery thin texture that feels dry to the touch. Usually flaky and dull looking.]
Normal Skin	NCIT_C74593	[The pores are visible but not large. The skin texture is neither fine or thick and it neither feels dry or oily to the touch.]
Nutlin-3a	NCIT_C74594	[A small molecule and MDM2 (murine double minute 2) inhibitor, with potential antineoplastic activity. In cancer cells, nutlin-3a antagonizes the binding of MDM2 to p53, thereby preventing MDM2-mediated p53 degradation. This results in stabilizing and activating p53-dependent cell cycle arrest and apoptosis. The protein MDM2, a negative regulator of p53 activity, is overexpressed in many cancer cell types; the tumor suppressor p53 is mutated or deleted in about 50% of all cancers but active in the other 50%.]
Protocol Disposition Event	NCIT_C74590	[The group of incidents that occur during a clinical trial and describe whether a subject completed the study epoch or the reason this event did not occur. The subject's disposition is often described for each phase of the study.]
Protocol Event	NCIT_C74589	[Other important events that occur during a trial but are not driven by protocol requirements.]
Protocol Milestone	NCIT_C74588	[Occurrences within some epochs that are initiated by a protocol-specified event. The most common protocol milestone is "Informed Consent Obtained" which usually documents the start of the study.]
Milestone	NCIT_C70743	[An important event in the progress, development, or history of something or in someone's life.]
Event	NCIT_C25499	[Something that happens at a given place and time.]
Lanreotide Acetate	NCIT_C74584	[The acetate salt of a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I). This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.]
Indinavir Anhydrous	NCIT_C74585	[An anhydrous formulation of indinavir, a synthetic hydroxyaminopentane amide agent that selectively inhibits the protease of both human immunodeficiency virus 1 and 2. The incorporation of a basic amine into the hydroxyethylene backbone improves its aqueous solubility and its oral bioavailability.]
HIV Protease Inhibitor	NCIT_C97366	[A protease inhibitor that is designed to target the human immunodeficiency virus (HIV) protease while sparing other host cell proteases. HIV protease mediates the cleavage of viral Gag, Gag-Pol and Nef precursor polypeptides into their mature proteins. Inhibition of HIV protease results in production of noninfectious viral particles.]
Cytochrome P450 3A7	NCIT_C46000	[Cytochrome P450 3A7 (503 aa, ~58 kDa) is encoded by the human CYP3A7 gene. This protein plays a role in the oxidation of steroids, fatty acids, and xenobiotics.]
Cytochrome P450 3A4	NCIT_C17573	[Cytochrome P450 3A4 (503 aa, ~57 kDa) is encoded by the human CYP3A4 gene. This protein is involved in the oxidation of steroids, fatty acids and xenobiotics.]
Cytochrome P450 3A5	NCIT_C45999	[Cytochrome P450 3A5 (502 aa, ~57 kDa) is encoded by the human CYP3A5 gene. This protein is involved in the oxidation of steroids, fatty acids, and xenobiotics.]